内皮KLF11是一种新型的抗糖尿病动脉样硬化保护剂
Guizhen Zhao1,2, Yang Zhao1, Wenying Liang3
1Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, 48109, USA.
Cardiovascular diabetology
|October 27, 2024
概括
内皮克鲁佩尔样因子11 (KLF11) 通过抑制炎症和氧化应激来保护糖尿病动脉样硬化. 失去KLF11会加快疾病的发展,这表明KLF11是糖尿病并发症的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 内分泌学 在内分泌学.
- 分子医学是分子医学.
背景情况:
- 糖尿病动脉样硬化是死亡的主要原因,由内皮细胞 (EC) 功能障碍引起.
- 克鲁佩尔样因子11 (KLF11) 涉及糖尿病的发展和血管平衡.
- KLF11在糖尿病动脉样硬化中的特定作用以前是未知的.
研究的目的:
- 为了研究内皮KLF11在糖尿病动脉样硬化的发病过程中的作用.
- 为了确定KLF11在糖尿病条件下如何影响内皮细胞功能障碍.
主要方法:
- 在EC特定的KLF11转基因和淘汰赛小鼠 (Ldlr-/-) 中诱导了糖尿病动脉样硬化.
- 单细胞RNA测序 (sc-RNA seq) 用于分析ECs.
- 在体外功能增加和丧失研究中,研究了KLF11在高葡萄糖诱导的EC功能障碍中的作用.
主要成果:
- 在糖尿病小鼠中,内皮KLF11缺乏加速了动脉样硬化;KLF11过度表达抑制了它.
- 在糖尿病条件下,KLF11损失增加了内皮细胞到介质细胞的过渡 (EndMT).
- 在高葡萄糖中,KLF11抑制了炎症激活,TXNIP诱导的氧化应激,以及Notch1/Snail介导的EndMT.
结论:
- 内皮KLF11作为抗糖尿病动脉样硬化的一种内源性保护因子.
- KLF11操纵为糖尿病相关的心血管并发症提供了潜在的治疗策略.
相关概念视频
Atherosclerosis I: Introduction
1
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K


